The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer

BACKGROUND: Brain metastasis is common in non-small cell lung cancer (NSCLC) and has an even higher incidence in epidermal growth factor receptor (EGFR)-mutant cancers. Although EGFR tyrosine kinase inhibitors (TKIs) are effective against brain metastases, it is unknown which first- or second-genera...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Hyun Ae, Woo, Sook Young, Lee, Se-Hoon, Ahn, Jin Seok, Ahn, Myung-Ju, Park, Keunchil, Sun, Jong-Mu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653133/
https://www.ncbi.nlm.nih.gov/pubmed/33209598
http://dx.doi.org/10.21037/tlcr-20-379

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653133/
https://www.ncbi.nlm.nih.gov/pubmed/33209598
http://dx.doi.org/10.21037/tlcr-20-379

Ejemplares similares